Industry Reports

Catalyst Pharmaceutical Partners, Inc. (CPRX) - Financial and Strategic SWOT Analysis Review

Tuesday, Oct 06, 2015

Catalyst Pharmaceutical Partners, Inc. (Catalyst) is a development-stage specialty pharmaceutical company. It focuses on the development and commercialization of prescription drugs targeting rare neurological and neuromuscular diseases which include infantile spasms, complex partial seizures, Lambert-Eaton Myasthenic Syndrome (LEMS), and Tourette syndrome. Its product portfolio includes products such as Firdapse, for the treatment of LEMS; CPP-115, for the treatment of infantile spasms and West syndrome; CPP-109, an add-on treatment for adult epilepsy and also as a primary treatment for the management of infantile spasms.

Read More>